Avalo Therapeutics Appoints Michael Heffernan as Chairman of the BoardWAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation, today announced the appointment of Michael Heffernan as Chairman of the Board of Directors (“Board”). Mr. Heffernan will succeed Dr. Garry Neil as Chairman of the Board. Dr. Neil will continue as a Board member and Chief Executive Officer (CEO) of the Company.
Why Trevi Therapeutics Could Be a Triple-Bagger Biotech StockWall Street analysts see big potential upside for small-cap biopharma firm Trevi Therapeutics. So, what does the firm do and how does it stand out?
Trevi Therapeutics, Inc. Discusses Commercialization for Its Investigational Therapy, Haduvio, with The Stock Day PodcastPhoenix, Arizona--(Newsfile Corp. - August 22, 2022) - The Stock Day Podcast welcomed Trevi Therapeutics, Inc. (
NASDAQ: TRVI) ("the Company"),...
Traders News Source Senior Editor Mark Roberts Interviews Jennifer Good CEO of Trevi TherapeuticsNEW YORK, NY / ACCESSWIRE / July 14, 2022 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap publicly traded companies recently issued a new C-Level interview with Trevi Therapeutics. Mark Roberts, Senior Editor at Traders News Source had the opportunity to conduct the interview featuring Jennifer Good Chief Executive Officer at Trevi Therapeutics.
5 Best Performing Micro-Cap Stocks Through the First Half of 2022The first half of 2022 is finally in the books and it could not have come sooner. Major U.S. indices
